A$821 Million NPV Frames CMG’s Lindfield Vanadium Development
Critical Minerals Group has put a substantial economic case around its Lindfield vanadium project, but its FY26 accounts also flag a material uncertainty over funding. The company is targeting a 2027 investment decision while holding less than A$1 million in year-end cash and navigating a leadership change.
- A$821 million pre-tax NPV and 26.6% IRR for Lindfield
- 31-year mine life with approximately A$981 million capital cost
- FY26 loss widened to A$3.82 million
- A$822,898 cash at 30 June 2026
- Funding, approvals and binding offtake remain critical
Lindfield Economics Set a High Bar
Critical Minerals Group Limited (ASX:CMG) has produced a sizeable headline for a company still operating without revenue: its preferred Lindfield vanadium development case carries a pre-tax net present value of A$821 million and a pre-tax internal rate of return of 26.6%.
The figures come from the pre-feasibility study released after the 30 June year end. The scenario combines a 3 million-tonne-per-year open-cut mine near Julia Creek in Queensland with a vanadium electrolyte facility at Parkes in New South Wales. It assumes a 31-year mine life, average vanadium pentoxide production of about 10,500 tonnes a year for the first 16 years, approximately A$981 million in capital expenditure and a peak funding requirement of A$736 million.
CMG says the production target includes both Indicated and Inferred Mineral Resources, meaning the project still requires further drilling and technical work before a maiden Ore Reserve can be established. The company plans to advance a Definitive Feasibility Study, with a Final Investment Decision targeted for calendar 2027.
The Staged Plan Brings Revenue Forward
The company is not proposing to build the mine and electrolyte business simultaneously. Its preferred sequence brings the Parkes electrolyte plant online first, using third-party vanadium pentoxide feedstock before transitioning to Lindfield production once the mine is developed.
That approach is intended to bring potential first revenue forward to 2028, build customer and offtake relationships earlier, and reduce peak funding exposure compared with a single integrated construction programme. The planned Phase 1 facility is designed for 24 million litres of electrolyte a year, while CMG has paused further spending on its smaller Crestmead facility.
The strategy has a more immediate commercial hurdle: the report says non-binding offtake discussions must progress to binding agreements, alongside reagent supply arrangements, pilot-scale metallurgical work, environmental approvals and concessional funding applications. The PFS may have established an attractive project case, but the next stage is about converting that case into something financeable.
Cash Position Keeps Funding Risk Front and Centre
CMG’s accounts show why financing remains central to the story. The group recorded a net loss of A$3.82 million in FY26, up from A$2.68 million a year earlier, and used A$3.14 million in operating cash. Exploration and evaluation spending added A$980,680 of investing outflows.
Cash fell from A$1.26 million to A$822,898 at 30 June, despite two placements that raised a combined A$3.3 million before costs. The financial statements explicitly identify a material uncertainty that may cast significant doubt on the group’s ability to continue as a going concern. Directors say their assessment depends on further capital, potential shareholder support, a possible Idemitsu loan facility, government funding and expenditure controls.
That possible Idemitsu facility is not yet a funding source in practice: the report says the loan agreement and security interest had not been executed, no funds had been drawn and no security had been enacted at the reporting date. The company also says a federal IPCM grant is suspended after delays at the Townsville-based QRCUF shared processing facility affected some milestones.
Leadership Change Adds Another Execution Variable
Scott Winter resigned as chief executive and managing director on 1 September 2026, after the reporting period, with Patrick Kelly appointed interim CEO. The board says FY27 will focus on the DFS, pilot plant testing, drilling, environmental studies, offtake negotiations and funding discussions with Australian and US government agencies.
The company’s cash runway, the status of any Idemitsu financing, the suspended grant and the quality of the eventual Ore Reserve will therefore matter at least as much as the PFS headline. CMG has a project case to advance, but the 2027 investment decision will require more than a strong model: it will require capital, approvals and customers to arrive in sequence.
Bottom Line?
CMG’s PFS provides a substantial valuation framework, but the near-term investment question is whether the company can fund the DFS and reach binding offtake before its limited cash position forces another capital raise.
Questions in the middle?
- How quickly can CMG secure additional funding and formalise the proposed Idemitsu facility?
- Will further drilling convert enough of the Indicated and Inferred resource into an Ore Reserve?
- Can the Parkes electrolyte strategy secure binding offtake and approvals in time for a 2027 investment decision?